I (and a number of my colleagues both here and abroad) believe that many of the findings reported by Belinsky et al. (1) were already in the public domain and that the discussion by these authors of previously published work did not make this clear. In addition, it is disappointing that Belinsky et al. have chosen to continue using the acronym MOAT (multispecific organic anion transporter) for members of the MRP (multidrug resistance protein)-related gene/protein family, despite the fact that the ABC (adenosine triphosphate-binding cassette) proteins they describe have been known as MRP5 (MOAT-C) and MRP3 (MOAT-D) since 1997 (2, 3) . Continued use of this nomenclature is certain to create unnecessary confusion in a field that is already difficult to follow because of the rapidity with which members of this large gene/protein superfamily continue to be discovered.
In their paper, Belinsky et al. report the following: 1) the full-length complementary DNA (cDNA) sequence of MRP5, which is predicted to encode a 1437-amino-acid protein; 2) the fulllength cDNA sequence of MRP3, which is predicted to encode a 1527-amino-acid protein; 3) the mapping of the MRP5 and MRP3 genes to chromosomes 3q27 and 17q21.3, respectively; and 4) the tissue distributions of MRP5 and MRP3 messenger RNAs (mRNAs).
To the best of my knowledge, Belinsky et al. are the first to publish the complete sequence of the MRP5 cDNA. However, a partial cDNA sequence (encoding approximately 1000 amino acids), the chromosomal localization of the gene, and the tissue distribution of the mRNA were previously published by Kool et al. (2) 
RESPONSE
Within a 13-week period, our laboratory (1) and two other research groups (2,3) reported characterizations of MRP (multidrug resistance protein)/cMOAT (multispecific organic anion transporter)-related transporters. All three studies described the predicted structures of human complementary DNAs (cDNAs) whose complete coding sequences had not previously been reported in the peer reviewed literature. Our laboratory had previously reported MOAT-B (MRP4) (4), the first complete coding sequence of an MRP/ cMOAT-related transporter, and in Belinsky et al.
(1), we described the complete coding sequences of MOAT-C (MRP5/SMRP [S ‫ס‬ short]) and MOAT-D (MRP3/cMOAT2). As the only laboratory to describe the complete coding sequences of 3 MRP/cMOATrelated transporters, we were afforded the opportunity to make a novel and informative comparison of the complete predicted structures of five members of the MRP/cMOAT subfamily. Analysis of the complete predicted structures and the resulting structural definition of this subfamily was the clear thrust of our study. We thank Dr. Cole for clarifying that the reports we referenced described tissue distributions and chromosomal localizations obtained with the use of partial sequences-referred to as MRP3 and MRP5/SMRP-of MOAT-D and MOAT-C, respectively, and for pointing out that the rat orthologue of MOAT-D/ MRP3 had been recently reported (5) . However, since the first peer-reviewed publications in which the complete MOAT-D/MRP3 sequence was described appeared only 13 weeks (3) and 3 weeks (2) before our study, the implication that our study concerning the complete coding sequences of both MOAT-C/MRP5 and MOAT-D/MRP3 was not timely is unfounded. In addition, we do not agree that the nomenclature for the MRP/cMOAT-related transporters has been firmly resolved in the literature. For example, Uchiumi et al.
(2) suggest cMOAT2 for the cDNA we termed MOAT-D and the partial sequence another group termed MRP3 (6) . As in any rapidly breaking field, research groups that have independently isolated MRP/cMOAT-related cDNAs have given them the names that they feel best represent the potential functions of the encoded proteins. In our case, we chose to conform to the nomenclature proposed in 1996 by Saxena et al. (7) , who suggested using MOAT, a term that has been used for more than a decade to describe organic anion transport activity. We believe that MOAT is appropriate from a historic point of view and may also prove to be accurate in terms of the biochemical and biologic activities of this subfamily (i.e., as a group, we believe these proteins are more likely to be organic anion transporters than they are to confer resistance to multiple natural product drugs). The indicated web sites are interesting, but not informative in terms of settling nomenclature in that one site suggests neither MOAT nor MRP for new members of this subfamily; instead, it proposes denoting family members as ABCC1 through ABCC5. As in other fields, we anticipate that a single nomenclature will evolve once all of the MRP/ cMOAT-related cDNAs have been reported in the literature.
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